tbuckley/cabot-search huggingface dataset:
Treatment modality and outcome of small round cell tumors in adults: Single-institution experience.
Authors: I. I. Cedrych, B. Pilecki, A. Kaminski, J. Strojek, T. Rutkowski, A. Wygoda, M. Golen, M Hutnik, W. Przeorek, B. Lukaszczyk, K. Skladowski
Journal: Journal of Clinical Oncology (2010)

e20517 Background: Round cell tumors are rare in adults and the treatment methods and outcome are still unsatisfactory. The aim of the study was to analyze the treatment outcome in the group of adult patients with small round cell tumors treated between 1998- 2008 in Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch. Methods: The group of 37pts (female 25/67%, male 12/33%) in median age 25 years (range 14-48) was analyzed. The most frequent diagnosis was Ewing sarcoma (18pts/49%), PNET (8pts/22%), Rhabdomyosarcoma (9pts/24%), Askin tumor. In the rest of patients. In 19pts/54% the primary tumor was localized on an extremity. Radical surgery was delivered to 10 pts/27% as an initial treatment, in 8 pts/22% complete surgery was preformed after initial chemotherapy, 26pts/70% were treated with radiotherapy with median total dose 54Gy (range 20-66). All patients received chemotherapy with the median number of 6 cycles (range 2-8). Twelve patients were eligible to receive second line chemotherapy because of disease progression/relapse. In 35pts the grade 3 and 4 toxicity according to WHO criteria was observed. Results: Twenty two patients (59%) responded to the treatment, CR was achieved in 18pts/48%. Within the median follow up of 24 months (range 4-117) the relapse was observed in 17pts/46%, 14 pts/38% have died. Median disease-free survival (DFS) was 15 months, estimated 5 year DFS according to Kaplan- Meyer method was 20%. Estimated 5 year overall survival (OS) was 62%. Radiotherapy did not affected survival. Radical surgery was the most important treatment modality for better outcome in patients who had undergone complete tumor excision the median DFS was 35 months versus 18 months in those without radical surgery (log rank p = 0.002). Conclusions: In the group of adult patients with small round cell tumors OS was fairly good despite short DFS. Then the role of radical surgery and chemotherapy even in relapsed or disseminated patients should be emphasized. No significant financial relationships to disclose.
Education to improve quality of life of people with chronic inflammatory skin conditions: a systematic review of the evidence
Authors: K. Pickett, G. Frampton, E. Loveman
Journal: British Journal of Dermatology (2016)

Patient and carer education has been proposed as a way of improving health-related quality of life (HRQoL) among people with chronic inflammatory skin conditions. This systematic review aimed to assess the effects of education that specifically addresses HRQoL among people with chronic inflammatory skin conditions. We searched 12 literature databases and other sources (up to July 2014). Seven randomized controlled trials (RCTs) met the review inclusion criteria. Data from these RCTs were extracted and critically appraised. Two RCTs showed that for psoriasis in adults, group-based and text message education (as adjuncts to usual care) resulted in better HRQoL and disease severity outcomes than comparators, respectively. One RCT found that group-based education for children with eczema (atopic dermatitis) and their parents resulted in greater improvements in parents' HRQoL and in the children's disease severity than no education at 12 months. The remaining RCTs evaluated an educational session for psoriasis, a website for carers of children with eczema, information on skincare and make-up use given to women with acne, and an itch-coping programme for a range of conditions, all as adjuncts to usual care. None of these RCTs found statistically significant effects on HRQoL or disease severity compared with usual care. Common features of the effective interventions were long delivery (over 6 weeks to 3 months) and delivery by a multidisciplinary team. Overall, the evidence base is currently limited and generally has an unclear risk of bias. There is a need for more large RCTs evaluating piloted and theory-based interventions.
Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease
Authors: Panu K. Luukkonen, You Zhou, Sanja Sädevirta, Marja Leivonen, Johanna Arola, Matej Orešič, Tuulia Hyötyläinen, Hannele Yki-Järvinen
Journal: Journal of Hepatology (2016)
Duration of Prehospital Resuscitation Efforts After Out-of-Hospital Cardiac Arrest
Authors: Ken Nagao, Hiroshi Nonogi, Naohiro Yonemoto, David F. Gaieski, Noritoshi Ito, Morimasa Takayama, Shinichi Shirai, Singo Furuya, Sigemasa Tani, Takeshi Kimura, Keijiro Saku
Journal: Circulation (2016)

During out-of-hospital cardiac arrest, it is unclear how long prehospital resuscitation efforts should be continued to maximize lives saved.Between 2005 and 2012, we enrolled 282 183 adult patients with bystander-witnessed out-of-hospital cardiac arrest from the All-Japan Utstein Registry. Prehospital resuscitation duration was calculated as the time interval from call receipt to return of spontaneous circulation in cases achieving prehospital return of spontaneous circulation or from call receipt to hospital arrival in cases not achieving prehospital return of spontaneous circulation. In each of 4 groups stratified by initial cardiac arrest rhythm (shockable versus nonshockable) and bystander resuscitation (presence versus absence), we calculated minimum prehospital resuscitation duration, defined as the length of resuscitation efforts in minutes required to achieve ≥99% sensitivity for the primary end point, favorable 30-day neurological outcome after out-of-hospital cardiac arrest. Prehospital resuscitation duration to achieve prehospital return of spontaneous circulation ranged from 1 to 60 minutes. Longer prehospital resuscitation duration reduced the likelihood of favorable neurological outcome (adjusted odds ratio, 0.84; 95% confidence interval, 0.838-0.844). Although the frequency of favorable neurological outcome was significantly different among the 4 groups, ranging from 20.0% (shockable/bystander resuscitation group) to 0.9% (nonshockable/bystander resuscitation group; P<0.001), minimum prehospital resuscitation duration did not differ widely among the 4 groups (40 minutes in the shockable/bystander resuscitation group and the shockable/no bystander resuscitation group, 44 minutes in the nonshockable/bystander resuscitation group, and 45 minutes in the nonshockable/no bystander resuscitation group).On the basis of time intervals from the shockable arrest groups, prehospital resuscitation efforts should be continued for at least 40 minutes in all adults with bystander-witnessed out-of-hospital cardiac arrest.URL: http://www.umin.ac.jp/ctr/. Unique identifier: 000009918.
Preliminary results of an open label, uncontrolled, multicenter, phase II study evaluating the efficacy and safety of xelox plus cetuximab as first-line therapy in patients with metastatic colorectal cancer
Authors: S. A. Barroso, E. Sanches, J. M. Ferreira, M. Passos, A. Sá, R. Nabiço, C. Sottomayor, J. Espírito Santo, R. San-Bento
Journal: Journal of Clinical Oncology (2008)

15010 Background: At present, there are limited data available for the use of cetuximab in combination with Oxaliplatin and Capecitabine, in the first line treatment of metastatic colorectal cancer. This study aimed to determine the efficacy and safety of the combination Xelox and Cetuximab in this setting. Methods: Patients received intravenous Oxaliplatin 130mg/m2 (3h-day 1) plus oral Capecitabine 1,000mg/m2 twice daily (days 1–14) every 3 weeks (Xelox) and intravenous Cetuximab 400mg/m2 in week 1 followed by weekly doses of 250mg/m2. Treatment was continued until disease progression, intolerable toxicities or 8 cycles were reached. This study aimed to include 45 patients to obtain a 95%CI for the overall response rate (ORR-primary endpoint) with a maximum width of 15% assuming an ORR of 50–80%. Patients will be followed until death. Results: The ITT population of 49 patients was enrolled between September 2005 and January 2007. Mean age was 60 years (range:44–75 years) and 66% of patients were male. The ECOG performance status was zero in 56.2% of the patients and 72.9% of the patients had distant metastasis. 31 patients were evaluable for response in cycle 5. One patient (3.2%) achieved a CR, 17 (54.8%) had PR, 9 (29.0%) had SD, 2 (6.5%) had PD and 2 (6.5%) were non- evaluable. The ORR was 58% (95%CI:40.6%-75.4%) and the TTP was 12 months (95%CI:9.2–14.8 months). Survival and quality of life data will be available soon. 48 patients were evaluable for toxicity. 11.5% of the adverse events (AEs) were grade 3/4. 77.1% of the patients had skin rash but only 8.3% had grade 3/4. Other grade 3/4 toxicities included diarrhea (n=7;14.6%), changes in potassium (n=6;12.5%), fatigue (n=2;4.2%) and thrombosis (n=1;2.1%). 2.7% of the AEs led to dose reduction, 7.3% to dose delay and 0.3% to infusion rate reduction. 25 (52.1%) patients were discontinued: 8 (16.7%) due to AEs, 7 (14.6%) due to PD and 10 (20.8%) due to other reasons. Conclusions: Preliminary results show that an overall response was achieved in nearly 60% of the patients treated with the combination of Xelox and Cetuximab.In addition, this combination appears to be a well tolerated regimen. No significant financial relationships to disclose.
In vitro and in vivo radiation resistance associated with CD3 surface antigen expression in T-lineage acute lymphoblastic leukemia
Authors: FM Uckun, NK Ramsay, KG Waddick, W Jaszcz, M Chandan-Langlie, V Obuz, R Haake, K Gajl-Peczalska, JH Kersey, CW Song
Journal: Blood (1991)
Activity of the Src-kinase inhibitor AZD0530 in androgen-independent prostate cancer (AIPC): Pre-clinical rationale for a phase II trial
Authors: C. P. Evans, P. N. Lara, H. Kung, J. C. Yang
Journal: Journal of Clinical Oncology (2006)

14542 Background: Cells with neuroendocrine (NE) differentiation are found in prostate cancer and may facilitate the transition to AI by supplying alternate growth factors. Androgen deprivation further induces a subgroup of AI NE cells by transdifferentiation. We hypothesized that androgen receptor (AR)- and src kinase-mediated signaling participates in this NE progression, and tested inhibition using the src kinase inhibitor AZD0530. Methods: The neuropeptide gastrin-releasing peptide (GRP) was minimally expressed in androgen-sensitive LNCaP cells. LNCaP-GRP clones demonstrated androgen- and anchorage-independent growth, developed orthotopic tumors in castrated SCID mice &amp; activated PSA with nuclear localization of AR. LNCap-GRP clones &amp; xenografts showed activation of src kinase. Xenografts were recultured (LNCaP-Pro) &amp; grown in androgen-free soft agar or tissue culture either alone, with synthetic androgen R1881 or with inhibitors including: GRP monoclonal antibody 2A11, 10 μM antiandrogen bicalutamide, Src kinase inhibitors AZM475271, AZD0530 (5 μM) and PP2 (10 μM). Mice bearing orthotopic LNCaP-GRP tumors were treated orally with 50 mg/kg AZD0530 daily for 6 weeks. Results: Androgen-depleted soft agar colony counts showed that LNCaP-Pro cell proliferation was not stimulated by R1881 but was partially inhibited by 2A11 antibody or bicalutamide, when compared to controls. A combination of 2A11 &amp; bicalutamide resulted in significant growth reduction (p &lt; 0.05). R1881 mostly reversed the 2A11 inhibition. The Src kinase inhibitors AZM475271 &amp; PP2 showed greatest colony formation inhibition (p &lt; 0.05). AZD0530 inhibited growth in culture (not tested in soft agar) at micromolar concentrations. Testing in vivo inhibited primary tumor growth in 5 of 7 dosed mice (71%), but completely inhibited metastasis in all AZD0530-treated mice (compared with metastasis in 100% of controls). Conclusions: Neuropeptide-mediated AIPC growth is dependent on both GRP and AR. There appears to be a beneficial role for Src kinase inhibition in this model. A CTEP-sponsored phase II trial of the dual Src/Abl kinase inhibitor AZD0530 in AIPC has been initiated. (KO8 DK60748–01, 2RO1 DK/AG52659–04, DOD PC10520, Astra-Zeneca, NO1 CM17101). [Table: see text]
Carcinoma associated peripheral neuropathy (PN): Our experience
Authors: S. Bonicatto, L. Reuter, M. Lavezzaro, A. Mainella, C. Chiaramello, E. Troncoso, A. Barbero, E. Carinci, Y. Burgos, A. Figueredo
Journal: Journal of Clinical Oncology (2008)

20540 Background: PN occurs in almost 10% of cancer patients(pts). Tumours associated are lung, breast, gynaecological cancers, and lymphoma. The clinical findings are heterogeneous and the pathogenesis is unknown. Its incidence is high(up to 50%) in pts undergoing electrodiagnostic evaluation. The aim of the study was to asses the incidence of clinical PN in untreated newly diagnosed cancer pts. Methods: Longitudinal and prospective study. Pts with recent diagnosis of cancer without oncological treatment and PN were included. Ineligibility criteria included alcoholism, renal failure, hypothyroidism, diabetes mellitus, immunological illness, previous PN and nutritional deficiency. Neurological examination (NE) by a trained oncologist and a neurologist was performed to detect PN. We evaluated objective and subjective superficial sensibility; deep sensibility; muscle strength (Medical Research Council Scale, muscle atrophy); deep tendon reflexes; autonomic function. Following that, a nerve conduction study (NCS) and an electromyography (EMG) in the upper and lower limbs were performed. Results: From March/December 2006, 39 pts were enrolled. Pts characteristics included: median age: 58,6 (range 24–82), male/female: 24/15, Performance Status 0/1: 26/13. All pts have been evaluated with NE and 28 of them with NCS-EMG. NE revealed some kind of abnormality in 10 pts (25,64%). In this group: 100% showed disorders in deep sensibility; 30% autonomic dysfunction; 20% abnormalities in superficial sensibility; 20% hyporreflexia in the lower extremities;10% moderate weakness in lower limb muscles. 10pts showed clinical evidence of peripheral nerve dysfunction and 2 of them were confirmed by NCS-EMG as axonal neuropathy. Conclusions: In our cancer pts sample, a high incidence of clinical PN was observed. Abnormalities in deep sensibility were the most frequently observed disorder. Distal symmetrical sensorimotor neuropathy was the most frequent presentation. Electrophysiological studies characterize this disorder as a distal axonopathy. We concluded that it should be important to consider the diagnosis of PN in any pt with cancer and an unexplained neurological dysfunction. No significant financial relationships to disclose.
Multifocality and overall survival in retroperitoneal sarcoma
Authors: D. A. Anaya, G. Lahat, J. Liu, Y. Xing, J. N. Cormier, P. W. Pisters, D. C. Lev, R. E. Pollock
Journal: Journal of Clinical Oncology (2008)

10579 Background: The association of multifocal (MF) disease and overall survival (OS) in retroperitoneal sarcoma (RPS) has not been studied. Further, no standard definition of sarcomatosis is available. Our goal was to evaluate the effect of multifocality on OS and to create a prognostic-based definition of sarcomatosis. Methods: A retrospective analysis of 393 patients with primary or recurrent nonmetastatic RPS treated at a comprehensive cancer center between 1996 and 2006 was done. Baseline and treatment variables were compared in patients with unifocal (UF) and MF disease. A multivariate model was used to evaluate the association of multifocality and OS; this approach was used to identify prognostic factors in patients with MF disease. Results: Median follow-up for all patients was 69 months; 79 patients (20%) presented with MF disease. Five-year OS was less in MF patients as compared to UF individuals (31% vs. 60%, respectively; P < 0.0001). After adjusting for differences among the MF and UF groups, multifocality remained an independent predictor of worse OS (HR 1.73 [95%CI 1.19–2.53]; P = 0.04). In patients with MF only disease, multivariate analysis for OS identified > 7 tumors as an independent predictor of worse prognosis (HR 2.05 [95%CI 1.07–3.94]; P = 0.03). Additionally, non-atypical lipomatous tumor (ALT) histology trended to significance (HR 6.14 [95%CI 0.8–47.1]; P = 0.08). Patients with > 7 tumors had a 5-year OS of 7%; all had non-ALT histology and 71% had an incomplete resection. Conclusions: Multifocality is associated with worse overall survival in patients with primary and recurrent RPS. In MF disease patients, those with > 7 tumors and non-ALT histology have the worst prognosis. These features can be used to define sarcomatosis, thereby identifying patients who are most in need of effective systemic therapy. No significant financial relationships to disclose.
Abstract 15541: In-Hospital Mortality in Obese Patients With Cardiogenic Shock Complicating Non-ST- and ST-Elevation Myocardial Infarction
Authors: Sahil Khera, Dhaval Kolte, Chandrasekar Palaniswamy, Marjan Mujib, Wilbert S Aronow, Ali Ahmed, Gregg C Fonarow, William H Frishman
Journal: Circulation (2013)

Background: Previous studies have described ‘obesity paradox’ (lower short- and long-term mortality in obese as compared to non-obese patients) in acute coronary syndromes. However, data available ...
First International Sports Science and Sports Medicine Conference Newcastle upon Tyne, 20-22 August 2009 Abstracts of original communications
Journal: British Journal of Sports Medicine (2009)

The Libyan Challenge is a 190 km desert run and is one of the most extreme ultra distance races in the world. Athletes must be self sufficient, carrying food and nutrients in a backpack. In preparation for the event an interdisciplinary sports science team provided support to a 41-year-old elite athlete to assist in her goal of winning
the race. During consultation, the athlete expressed concerns about the effect of the environment and backpack on performance. The athlete had also suffered an acute achilles tendinopathy 15 weeks before the race, preventing her from running and affecting confidence.
The support team included a sports therapist, sports psychologist, physiologist, nutritionist, and strength and conditioning coach. Initial support focused on rehabilitation, consisting of a progressive eccentric
plantar flexion strength programme and previous success of an eccentric programme (3610 repetitions) in the contralateral limb. Return to running was assessed via isokinetic evaluation at speeds determined by prior biomechanical analyses. Simultaneously, a crosstraining
intervention maintaining aerobic conditioning was prescribed
with a progressive strength programme to increase leg
strength and neuromuscular stability. After successful rehabilitation, running was gradually introduced (11 weeks before race) until the athlete had returned to normal training (7 weeks before race). Appropriate nutrition that was non-perishable, easily ingested, energy dense and portable was identified and examined for feasibility in an
environmental chamber (38uC, 25% humidity) during maximal
running performance. Gradually specific backpack and sand running were introduced at 5 weeks and combined at 4 weeks. Two weeks prior to the event the athlete underwent a taper period and acclimatisation sessions (36 per week, 38uC). The athlete finished as the first female and broke the course record, with no reoccurrence of injury. This case study supports an interdisciplinary approach to
applied sports science as a model of good practice.
Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
Authors: B. Grana, H. A. Burris, J. Rodon Ahnert, A. R. Abdul Razak, M. J. De Jonge, F. Eskens, L. L. Siu, Q. C. Ru, N. F. Homji, D. Demanse, E. Di Tomaso, J. G. C. E. Cosaert, C. Quadt, J. Baselga, J. C. Bendell
Journal: Journal of Clinical Oncology (2011)

3043 Background: PI3K pathway is frequently altered in cancer and can have an impact on tumor survival and proliferation. BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor without mTOR and Vps34 activity. Methods: Phase I dose-escalation (DE) study followed by an expansion cohort of daily BKM120 in pts with advanced solid tumors. Bayesian logistic regression model with overdose control guided the DE. Pts in the MTD expansion arm were pre-selected for molecular alterations of PI3K and/or PTEN. Results: 77 pts received oral BKM120 once daily thus far; data on 66 pts, median age 55 y (30-77), are reported here. 6 dose levels were explored: 12.5 mg (1 pt); 25 mg (2 pts), 50 mg (5 pts), 80 mg (11 pts), 100 mg (43 pts), 150 mg (4 pts). Most common tumor types: CRC (24 pts), breast cancer (BC) (18 pts), lung (3 pts) and endometrial (3 pts) cancer. Median duration of treatment was 7.5 wks (0.1-69+) with 18 pts treated for >16 wks. Seven dose-limiting toxicities (DLTs) were observed: 2x G4 hyperglycemia (150mg/d), 1x G3 upper abdominal pain, 1x G3 skin rash, 2x G2 and 1x G3 mood alteration. MTD was 100 mg/d. Most frequent AEs of all grades and suspected to be drug-related were decreased appetite (33%), rash, diarrhea, nausea (each 27%), fatigue, hyperglycemia (each 24%), anxiety (20%), depression (18%), and mucositis (17%). Mood alterations were successfully managed using self-rating questionnaires. pS6 suppression was found in skin in 100 and 150 mg cohorts (30 to 80% decreases from baseline). Increase of C-peptide was observed at all doses suggesting potential impairment of glucose transport by BKM120. Partial tumor responses were observed in 2 pts: one TN-BC with KRAS and p53 mutation, and one ER+/HER2 neg mBC harboring PIK3CA mutation. 58% pts (26 of 45 evaluable) had SD as best response. Eighteen pts had SD > 16 wks, including 8 pts who had tumors with an activated PI3K pathway. A trend towards better activity was observed at the higher dose cohorts, also expressed as metabolic FDG-PET response. Conclusions: BKM120 monotherapy was well tolerated and showed biological and antitumor activity. Further exploration of BKM120 in patients with PI3K pathway alteration is ongoing in endometrial and lung cancer pts.
An integrative cross-tumors approach identifies FOSL1 as an oncogene dependency in KRAS-driven lung cancer
Authors: Adrian Vallejo, Naiara Perurena, Elizabeth Guruceaga, Pawel K. Mazur, Susana Martinez-Canarias, Carolina Zandueta, Dana Gwinn, Leanne C. Sayles, Chen-Hua Chuang, Jesper B. Andersen, Aline Bozec, Alejandro Sweet-Cordero, Julien Sage, Fernando Lecanda, Silvestre Vicent
Journal: Journal of Thoracic Oncology (2016)
Buparlisib (Bkm120) in Patients with Pi3K Pathway-Activated, Metastatic Non-Small Cell Lung Cancer (Nsclc): Results from the Basalt-1 Study
Authors: J-C. Soria, J.F. Vansteenkiste, J. Canon, M. Reck, C. Gridelli, F. Grossi, T. De Pas, J. Gray, E. Felip, W. Su, H. Yoshioka, G.K. Dy, M. Thomas, J. De Greve, P. Roussou, G. Atalla-Vidam, P. Aimone, S. Thongprasert
Journal: Annals of Oncology (2014)
A Phase I Study Of Panobinostat In Combination With ICE (Ifosfamide, Carboplatin and Etoposide) In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL)
Authors: Yasuhiro Oki, Michelle A. Fanale, Jason R. Westin, Nathan Fowler, Sattva S. Neelapu, Fredrick B Hagemeister, Maria Alma Rodriguez, Anas Younes
Journal: Blood (2013)